Your browser doesn't support javascript.
loading
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial.
Prince, H Miles; Kim, Youn H; Horwitz, Steven M; Dummer, Reinhard; Scarisbrick, Julia; Quaglino, Pietro; Zinzani, Pier Luigi; Wolter, Pascal; Sanches, Jose A; Ortiz-Romero, Pablo L; Akilov, Oleg E; Geskin, Larisa; Trotman, Judith; Taylor, Kerry; Dalle, Stephane; Weichenthal, Michael; Walewski, Jan; Fisher, David; Dréno, Brigitte; Stadler, Rudolf; Feldman, Tatyana; Kuzel, Timothy M; Wang, Yinghui; Palanca-Wessels, Maria Corinna; Zagadailov, Erin; Trepicchio, William L; Zhang, Wenwen; Lin, Hui-Min; Liu, Yi; Huebner, Dirk; Little, Meredith; Whittaker, Sean; Duvic, Madeleine.
Afiliación
  • Prince HM; Division of Cancer Medicine, Peter MacCallum Cancer Centre, The University of Melbourne, Melbourne, VIC, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, VIC, Australia; Epworth Healthcare, The University of Melbourne, Melbourne, VIC, Australia. Electron
  • Kim YH; Department of Dermatology, Stanford University School of Medicine, Stanford, CA, USA; Stanford Cancer Institute, Stanford, CA, USA.
  • Horwitz SM; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Dummer R; Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.
  • Scarisbrick J; Department of Dermatology, University Hospital Birmingham, Birmingham, UK.
  • Quaglino P; Department of Medical Sciences, Dermatologic Clinic, University of Turin, Turin, Italy.
  • Zinzani PL; Institute of Haematology, University of Bologna, Bologna, Italy.
  • Wolter P; Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium.
  • Sanches JA; Department of Dermatology, University of São Paulo Medical School, São Paulo, Brazil.
  • Ortiz-Romero PL; Department of Dermatology, University Hospital 12 de Octubre, Institute i+12 Medical School, University Complutense, Madrid, Spain.
  • Akilov OE; Department of Dermatology, University of Pittsburgh, Pittsburgh, PA, USA.
  • Geskin L; Department of Dermatology, University of Pittsburgh, Pittsburgh, PA, USA; Department of Dermatology, Columbia University, New York, NY, USA.
  • Trotman J; Department of Haematology, Concord Repatriation General Hospital, University of Sydney, Concord, NSW, Australia.
  • Taylor K; ICON Cancer Care, South Brisbane, QLD, Australia.
  • Dalle S; Department of Dermatology, Hospices Civils de Lyon, Claude Bernard Lyon 1 University, Lyon, France.
  • Weichenthal M; Department of Dermatology, University Hospital of Schleswig-Holstein, Kiel, Germany.
  • Walewski J; Maria Sklodowska-Curie Institute and Oncology Centre, Warsaw, Poland.
  • Fisher D; Dana-Farber Cancer Institute, Boston, MA, USA.
  • Dréno B; Faculty of Medicine, Nantes University, Nantes, France.
  • Stadler R; University Clinic for Dermatology, Johannes Wesling Medical Centre, Minden, Germany.
  • Feldman T; John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, NJ, USA.
  • Kuzel TM; Division of Hematology/Oncology/Cell Therapy, Department of Medicine, Rush University, Chicago, IL, USA.
  • Wang Y; Seattle Genetics Inc, Bothell, WA, USA.
  • Palanca-Wessels MC; Seattle Genetics Inc, Bothell, WA, USA.
  • Zagadailov E; Millennium Pharmaceuticals Inc, Takeda Pharmaceutical Company Ltd, Cambridge, MA, USA.
  • Trepicchio WL; Millennium Pharmaceuticals Inc, Takeda Pharmaceutical Company Ltd, Cambridge, MA, USA.
  • Zhang W; Millennium Pharmaceuticals Inc, Takeda Pharmaceutical Company Ltd, Cambridge, MA, USA.
  • Lin HM; Millennium Pharmaceuticals Inc, Takeda Pharmaceutical Company Ltd, Cambridge, MA, USA.
  • Liu Y; Millennium Pharmaceuticals Inc, Takeda Pharmaceutical Company Ltd, Cambridge, MA, USA.
  • Huebner D; Millennium Pharmaceuticals Inc, Takeda Pharmaceutical Company Ltd, Cambridge, MA, USA.
  • Little M; Millennium Pharmaceuticals Inc, Takeda Pharmaceutical Company Ltd, Cambridge, MA, USA.
  • Whittaker S; St John's Institute of Dermatology, Guys and St Thomas NHS Foundation Trust, London, UK.
  • Duvic M; The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Lancet ; 390(10094): 555-566, 2017 08 05.
Article en En | MEDLINE | ID: mdl-28600132
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Calidad de Vida / Linfoma Cutáneo de Células T Tipo de estudio: Clinical_trials Límite: Humans Idioma: En Año: 2017 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Calidad de Vida / Linfoma Cutáneo de Células T Tipo de estudio: Clinical_trials Límite: Humans Idioma: En Año: 2017 Tipo del documento: Article